Long-Acting Gonadotropin-Releasing Hormone Implant to Maintain Medical Castration for Two Years in Men with Prostate Cancer

Publisher Website
Google Scholar
Abstract
Medical castration with long-acting gonadotropin-releasing hormone agonists is an effective therapy for men with metastatic prostate cancer.1,2 Initially, these agonists had to be given daily, but depot preparations that can be administered at intervals of one to three months are now available.3,4 We describe here the response to a longer-acting implant releasing the gonadotropin-releasing hormone agonist histrelin (Hydron, Hydro Med Sciences) in men with prostate cancer.